| Literature DB >> 30976022 |
Fan Li1, Weiling Zhang1, Huimin Hu1, Yi Zhang1, Dongsheng Huang2.
Abstract
Infection is a fatal complication in cancer patients that sometimes is not distinguished from tumour progression. We compared the diagnostic value of procalcitonin (PCT), C-reactive protein (CRP) and lactate dehydrogenase (LDH) in paediatric malignant solid tumour concurrent with infection and tumour progression. The 152 children enrolled were divided into infection and control groups. Each group was divided further into stable and progression groups. An intergroup comparison was made in terms of serum PCT, CRP and LDH in all children. PCT, CRP and LDH levels were significantly higher in the infection than in the control groups (P < 0.05). Among the controls, PCT, CRP and LDH levels were significantly higher in the progression than in the stable groups (P < 0.05). In diagnosing infection, the sensitivity and specificity of PCT and CRP at the cutoff values of 0.296 ng/mL and 28.13 mg/L were relatively better than those at 0.5 ng/mL and 10 mg/L, respectively. LDH had the highest correlation with tumour progression, whereas PCT had the lowest (LDH, r = 0.684; CRP, r = 0.570; PCT, r = 0.322). Thus, PCT has the highest value in diagnosing infection and is less susceptible to tumour progression than CRP. LDH has obvious advantages in judging tumour progression.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30976022 PMCID: PMC6459850 DOI: 10.1038/s41598-019-42264-0
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Comparison of general data (age, sex, state of tumour, tumour types and other factors) in children with malignant solid tumour between infection and control groups.
| Infection group | Control group | Statistic value | ||
|---|---|---|---|---|
| Number of patients | 34 | 118 | ||
| Age [years, | 3(2.1) | 3(4.0) | 0.279 | |
| Gender [n (%)] | ||||
| Male | 16 (47.1) | 75 (63.6) | 0.084 | |
| Female | 18 (52.9) | 43 (36.4) | ||
| Tumour state [n (%)] | ||||
| Stable | 20 (58.8) | 74 (62.7) | 0.681 | |
| Progression | 14 (41.2) | 44 (37.3) | ||
| Tumour types [n (%)] | ||||
| Neuroblastoma | 10 (29.4) | 41 (34.7) | χ2 = 8.304 | 0.847 |
| Hepatoblastoma | 7 (20.6) | 27 (22.9) | ||
| Nephroblastoma | 7 (20.6) | 15 (12.7) | ||
| Rhabdomyosarcoma | 4 (11.8) | 14 (11.9) | ||
| PNET/Ewing’s sarcoma | 2 (5.9) | 6 (5.1) | ||
| Endodermal sinus tumour | 1 (2.9) | 3 (2.5) | ||
| Langerhans cell histiocytosis | 1 (2.9) | 3 (2.5) | ||
| Lymphoma | 0 (0) | 3 (2.5) | ||
| Osteosarcoma | 1 (2.9) | 1 (0.8) | ||
| Yolk sac tumour | 0 (0) | 2 (1.7) | ||
| Pulmonary blastoma | 0 (0) | 1 (0.8) | ||
| Pancreatoblastoma | 1 (2.9) | 0 (0) | ||
| Malignant germ cell tumour | 0 (0) | 1 (0.8) | ||
| Clear cell sarcoma of the kidney | 0 (0) | 1 (0.8) | ||
| Other factors [n (%)] | ||||
| Perioperative period | 7 (20.6) | 17 (14.4) | χ2 = 0.759 | 0.384 |
| Non-perioperative period | 27 (79.4) | 101 (85.6) | ||
Comparison of PCT, CRP and LDH levels between infection and control groups [M(Q)].
| Group | Number of cases | PCT(ng/mL) | CRP(mg/L) | LDH(U/L) |
|---|---|---|---|---|
| Infection group | 34 | 0.67(1.33) | 97.00(88.12) | 319.0(450.0) |
| Control group | 118 | 0.08(0.07) | 1.99(11.50) | 282.5(116.0) |
| Statistic value | — | |||
| — | 0.000 | 0.000 | 0.003 |
Number of cases and positive rates of PCT and CRP between infection and control groups [n (%)].
| Group | Number of cases | PCT | CRP |
|---|---|---|---|
| Infection group | 34 | 26(76.5%) | 32(94.1%) |
| Control group | 118 | 0(0%) | 31(26.3%) |
| Statistic value | — | ||
| — | 0.000 | 0.000 |
Serum PCT, CRP and LDH levels between the stable and progression groups among the infection and control groups [M(Q)].
| Group | Subgroup | Number of cases | PCT(ng/mL) | CRP(mg/L) | LDH(U/L) |
|---|---|---|---|---|---|
| Infection group | Stable group | 20 | 0.90(1.37) | 109.50(107.94) | 308.0(119.0) |
| Progression group | 14 | 0.52(1.32) | 57.01(92.49) | 606.0(2148.0) | |
| Statistic value | — | ||||
| — | 0.416 | 0.274 | 0.030 | ||
| Control group | Stable group | 74 | 0.07(0.06) | 0.94(2.16) | 256.0(81.0) |
| Progression group | 44 | 0.11(0.08) | 12.99(28.26) | 370.0(242.0) | |
| Statistic value | — | ||||
| — | 0.000 | 0.000 | 0.000 |
Figure 1ROC curve of PCT, CRP and LDH in diagnosing infection and tumour progression in children with malignant solid tumour. (a) In diagnosing infection, the area under the ROC curve was 0.997 (95% CI, 0.992~1.000), 0.935 (95% CI, 0.895~0.974) and 0.665 (95% CI, 0.557~0.774) for PCT, CRP and LDH, respectively. (b) In diagnosing tumour progression, the area under the ROC curve was 0.692 (95% CI, 0.590~0.795), 0.840 (95% CI, 0.768~0.912) and 0.908 (95% CI, 0.853~0.963) for PCT, CRT and LDH, respectively.
Sensitivity and specificity at different cutoff values in separate or combined diagnosis.
| Standard cutoff value | Optimal cutoff value | Cutoff at 100% specificity | Area under ROC curve | |
|---|---|---|---|---|
| Diagnosis of infection in all children | ||||
| PCT (ng/mL) | ≥0.5 | ≥0.296 | ≥0.377 | 0.997 |
| Sensitivity | 76.5% | 94.1% | 88.2% | |
| Specificity | 100% | 97.5% | 100% | |
| CRP (mg/L) | ≥10 | ≥28.13 | ≥168.18 | 0.935 |
| Sensitivity | 94.1% | 88.2% | 11.8% | |
| Specificity | 73.7% | 87.3% | 100% | |
| LDH (U/L) | ≥298.5 | ≥2610 | 0.665 | |
| Sensitivity | 70.6% | 11.8% | ||
| Specificity | 60.2% | 100% | ||
| PCT combined with CRP (in series) | 0.996 | |||
| Sensitivity | 72.0% | 83.0% | ||
| Specificity | 100% | 99.7% | ||
| PCT combined with CRP (in parallel) | ||||
| Sensitivity | 98.6% | 99.3% | ||
| Specificity | 73.7% | 85.1% | ||
| Diagnosis of progression in uninfected children | ||||
| PCT (ng/mL) | ≥0.094 | ≥0.252 | 0.692 | |
| Sensitivity | 70.5% | 13.6% | ||
| Specificity | 70.3% | 100% | ||
| CRP (mg/L) | ≥10 | ≥2.2 | ≥38.3 | 0.840 |
| Sensitivity | 52.3% | 75.0% | 22.7% | |
| Specificity | 89.2% | 73.0% | 100% | |
| LDH (U/L) | ≥295 | ≥300.5 | ≥391.5 | 0.908 |
| Sensitivity | 81.8% | 77.3% | 38.6% | |
| Specificity | 79.7% | 82.4% | 100% | |
| LDH combined with CRP (in series) | 0.944 | |||
| Sensitivity | 42.8% | 58.0% | ||
| Specificity | 97.8% | 95.2% | ||
| LDH combined with CRP (in parallel) | ||||
| Sensitivity | 91.3% | 94.3% | ||
| Specificity | 71.1% | 60.2% | ||
| Diagnosis of infection combined with tumor progression in all children | ||||
| Combination of three indices (in series) | 0.885 | |||
| Sensitivity | 57.1% | 71.4% | ||
| Specificity | 91.3% | 93.5% | ||
Figure 2ROC curve of combined detection in diagnosing infection and tumour progression in children with malignant solid tumour. (a) In the diagnosis of infection by PCT combined with CRP, the area under the ROC curve was 0.996 (95% CI, 0.990~1.000). (b) In the diagnosis of tumour progression by LDH combined with CRP, the area under the ROC curve was 0.944 (95% CI, 0.901~0.987). (c) In the diagnosis of infection with tumour progression by combination of three indices, the area under the ROC curve was 0.885 (95% CI, 0.817~0.952).